Mouse and mathematical models for HIV-1 suppression through HSPC
Mouse and mathematical models for HIV-1 suppression through HSPC
批准号:
8915902
负责人:
IRVIN S.Y. CHEN
金额:
$38.1万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-06 至 2016-08-31
关键词:
AddressAnimal ModelAnimalsAntiviral TherapyB-LymphocytesBiological ModelsBiological ProcessBloodCCR5 geneCase StudyCell TransplantsCellsClinical ResearchCoupledCytoprotectionDataDiseaseEngineered GeneEquationExtinction (Psychology)FailureFrequenciesGene CombinationsGene-ModifiedGenesGenetic Population StudyGoalsHIVHIV InfectionsHIV-1HealthHematopoieticHematopoietic stem cellsHomologous TransplantationHumanImmuneImmune systemIn VitroIndividualInfectionKineticsLeadLentivirus VectorLifeMacaca mulattaMeasurementModelingMusOrganismPhysiological ProcessesPopulationPrimatesProbabilityProtocols documentationPublishingRNAReagentRelative (related person)SiteStem cellsStructureSystemT cell differentiationT-LymphocyteTestingTherapeuticThymus GlandTimeTissuesTransplantationTreatment EfficacyViral Load resultcellular engineeringdesigndosagegene therapyimmune functionkillingsknock-downmacrophagemathematical modelmouse modelnonhuman primateperipheral bloodpreventreconstitutionsmall hairpin RNAstemtherapeutic gene
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We hypothesize that there exists critical "threshold" levels of repopulation with anti-HIV gene-marked cells above which protection of the immune system from HIV will be successful, and below which, HIV-1 infection will lead to immune system failure. The landmark genetic and population studies showing protection from HIV- 1 in CCR5Δ32 individuals coupled with the remarkable case study demonstrating cure by allogeneic transplantation of CCR5Δ32 hematopoietic stem/progenitor cells (HSPC) has led to numerous transplantation studies using cells engineered to knockdown CCR5 expression. However, determining the critical levels of repopulation after transplant necessary to cure or provide life-long suppression of HIV-1 has not been addressed. Given the expected low levels of gene-marking by anti-HIV-1 gene engineered cells in clinical studies, it is critical to understand the parameters for repopulation at which a minimum level of gene engineered cells protect the individual from HIV-1 infection and restore normal immune function. Establishing and understanding the immune parameters at this "threshold level" is critical for determining experimental conditions for transplant such that repopulation with gene engineered cells is therapeutically effective in preventing HIV-1 from killing the majority of unprotected cells. Testing the above hypothesis is impossible in humans and impractical in non-human primates, so we propose to extend our understanding of repopulation and protection from HIV-1 to a humanized small animal model system. The BLT mouse system is ideal for studying HSPC transplant since unlike other humanized mouse models, the transplanted human HSPC differentiate in the context of a human thymus allowing normal human T-cell differentiation and resulting in robust reconstitution of T-cells (as well as macrophages and Bcells) in peripheral blood and in all the major tissue sites of HIV-1 replication. We recently published in a rhesus macaque transplant model highly analogous to human transplant that thousands of HSPC clones contribute in temporal waves and by diverse lineage potential to repopulation. Like the simian model, we show that repopulation in BLT mice is polyclonal. Transplant can be experimentally manipulated to model different parameters of repopulation with anti-HIV gene engineered cells. To analyze our observations and measurements of T-cells, we will develop mathematical models that capture the key biological processes. Such models will not only help define threshold levels of transplantation, but will also allow one to make systematic predictions under different transplant protocols and experimental conditions. For example, the effects of gene therapeutic reagent and transplantation dosage can be directly investigated. Moreover, by including known equations describing the kinetics of HIV-1 infection, viral loads, the influence of
different combinations of antiviral therapies, and the probabilities of extinction and total HIV-1 clearance in organisms can also be explored.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
A Hierarchical Kinetic Theory of Birth, Death and Fission in Age-Structured Interacting Populations.
DOI:
10.1007/s10955-016-1524-x
发表时间:
2016
期刊:
Journal of statistical physics
影响因子:
1.6
作者:
[Chou T, Greenman CD]
通讯作者:
Greenman CD
Fixation times in differentiation and evolution in the presence of bottlenecks, deserts, and oases.
在存在瓶颈、沙漠和绿洲的情况下分化和进化的固定时间。
DOI:
10.1016/j.jtbi.2015.02.021
发表时间:
2015
期刊:
Journal of theoretical biology
影响因子:
2
作者:
[Chou,Tom, Wang,Yu]
通讯作者:
Wang,Yu
DOI:
10.1007/s11538-019-00630-z
发表时间:
2019-07-01
期刊:
BULLETIN OF MATHEMATICAL BIOLOGY
影响因子:
3.5
作者:
[Lewkiewicz, Stephanie, Chuang, Yao-li, Chou, Tom]
通讯作者:
Chou, Tom
Administrative Core
-
批准号:10160815
-
项目类别:
-
资助金额:$19.44万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Administrative Core
-
批准号:10614634
-
项目类别:
-
资助金额:$18.74万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
-
批准号:10468647
-
项目类别:
-
资助金额:$284.77万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
-
批准号:10614633
-
项目类别:
-
资助金额:$284.81万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
-
批准号:10160814
-
项目类别:
-
资助金额:$284.79万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
-
批准号:9890819
-
项目类别:
-
资助金额:$287.22万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Administrative Core
-
批准号:10468648
-
项目类别:
-
资助金额:$20.05万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
In Vivo Gene Editing for HIV-1 Cure
-
批准号:10549758
-
项目类别:
-
资助金额:$67.8万
-
财政年份:2019
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
In Vivo Gene Editing for HIV-1 Cure
-
批准号:10331787
-
项目类别:
-
资助金额:$67.8万
-
财政年份:2019
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
In Vivo Gene Editing for HIV-1 Cure
-
批准号:9753575
-
项目类别:
-
资助金额:$67.8万
-
财政年份:2019
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Anti-HIV Gene Therapy: Defend and Attack
-
批准号:8899031
-
项目类别:
-
资助金额:$225.61万
-
财政年份:2015
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Anti-HIV Gene Therapy: Defend and Attack
-
批准号:9468343
-
项目类别:
-
资助金额:$195.65万
-
财政年份:2015
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Anti-HIV Gene Therapy: Defend and Attack
-
批准号:9249485
-
项目类别:
-
资助金额:$213.55万
-
财政年份:2015
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification
-
批准号:9264595
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification
-
批准号:9058597
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification
-
批准号:8906934
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Gene engineering using CRISPR/Cas9 mutagenesis to eliminate latent HIV-1
-
批准号:8789998
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification
-
批准号:8790285
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Hematopoietic stem/progenitor cell reservoirs
-
批准号:8659761
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2013
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Hematopoietic stem/progenitor cell reservoirs
-
批准号:9171938
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2013
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
海外基金